MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 05-16-2026
Syneos Health Interest Expense 2011-2026 | SYNH
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Syneos Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.4 M | 79.3 M | 91.1 M | 130 M | 131 M | 63.7 M | 12 M | 15.6 M | 53 M | 60.8 M | 62.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 131 M | 12 M | 71 M |
Quarterly Interest Expense Syneos Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.9 M | 26.8 M | - | 22.1 M | 18.1 M | 15.8 M | - | 16.7 M | 22.6 M | 23.3 M | - | 20.4 M | 21.7 M | 26.5 M | - | 32.6 M | 34.3 M | 34.6 M | - | 33.1 M | 32.9 M | 31.7 M | - | 27.4 M | 3.29 M | 3.1 M | - | 3.23 M | 3.09 M | 3 M | - | 3.06 M | 4.23 M | 5.39 M | - | 12.9 M | 12.8 M | 16.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 37.9 M | 3 M | 18.9 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
5.33 M | $ 88.78 | -3.99 % | $ 4.15 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
106 K | $ 5.1 | -11.46 % | $ 6.78 M | USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 19.04 | -2.36 % | $ 586 M | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 21.38 | -1.02 % | $ 620 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 126.94 | -4.6 % | $ 15.9 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.79 | 2.29 % | $ 7.92 M | USA |
 |
Illumina
ILMN
|
340 M | $ 162.14 | -3.52 % | $ 25.1 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 22.29 | -3.59 % | $ 1.19 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 149.1 | -2.42 % | $ 11.7 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 103.22 | 0.39 % | $ 6.97 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
17.6 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 10.96 | -3.09 % | $ 1.4 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 183.58 | -1.2 % | $ 9.1 B | USA |
 |
Natera
NTRA
|
4.07 M | $ 217.28 | -2.17 % | $ 29.7 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 454.91 | -0.82 % | $ 13.1 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.46 | -10.74 % | $ 438 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 157.67 | -1.93 % | $ 23.9 B |  Schweiz |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.65 | -0.85 % | $ 431 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 19.5 | -1.27 % | $ 436 M | USA |
 |
Personalis
PSNL
|
205 K | $ 11.17 | -7.69 % | $ 997 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.21 | 0.81 % | $ 24.9 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.78 | -3.28 % | $ 283 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.58 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.21 | 3.03 % | $ 5.08 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.33 | 1.23 % | $ 22 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 70.6 | -4.51 % | $ 4.22 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 474.92 | -1.49 % | $ 179 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.72 | 4.53 % | $ 259 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 8.96 | -1.81 % | $ 1.94 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 200.0 | 1.96 % | $ 22.2 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |